Mission to Reinvigorate Growth through Optimization of Mass Cytometry and Microfluidics Platforms and Portfolio Expansion via Strategic Acquisitions Dr. Michael Egholm , Former CTO of Danaher Life Sciences, to Assume Role of CEO and Join Board of Directors Following Close; Alex Kim , Former
Fourth quarter preliminary revenue of $38.0 to $38.3 million Full year 2021 preliminary revenue of $130.3 to $130.6 million Base product and service revenue growth of approximately 13% for fourth quarter and 12% for full year as new Biomark OEM and CyTOF XT instruments contributed to revenue SOUTH
No Published Viral Mutations to Date, Including Omicron Variant, Meaningfully Impact the Regions of the Viral Genome Targeted by the Assay SOUTH SAN FRANCISCO, Calif. , Dec. 07, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to
SOUTH SAN FRANCISCO, Calif. , Nov. 16, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Chris Linthwaite , President and CEO, and Vikram Jog, Chief
Streamlines Operations to Reduce Hands-On Time, Accelerate Results Broad Menu of Applications with Automated Workflow Providing Sample-to-Answer Solutions on a Single Platform SOUTH SAN FRANCISCO, Calif. , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative
Board Undertaking Review of Range of Value-Enhancing Opportunities SOUTH SAN FRANCISCO, Calif. , Nov. 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced
IMC Studies Part of New York Genome Center’s Polyethnic-1000 Initiative Advancing Understanding of Racial Disparities in the Prevalence of Cancer Types SOUTH SAN FRANCISCO, Calif. , Nov. 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with
SOUTH SAN FRANCISCO, Calif. , Oct. 20, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report third quarter 2021 financial results on Monday,
Latest Imaging Mass Cytometry Discoveries in Infectious Disease, Immuno-Oncology and the Tumor Microenvironment from Expert Users of the Technology SOUTH SAN FRANCISCO, Calif. , Oct. 18, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a
Native Reading of Hyperion Imaging System Data Files on the Visiopharm Platform to Streamline Data Analysis for Researchers SOUTH SAN FRANCISCO, Calif. , Oct. 12, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life
